Hikma Pharmaceuticals has agreed to acquire two nasal sprays as well as unit-dose nasal spray manufacturing assets from Insys Therapeutics, the company said. In June 2019, Insys declared bankruptcy and said that it would sell all of its assets. Hikma did not say how much it paid for the naloxone and epinephrine nasal sprays.
Insys announced results from a dose finding study of the epinephrine nasal spray at the beginning of 2019. The FDA had granted Fast Track designation to the epinephrine nasal spray for the treatment of anaphylaxis in August 2018. In July 2019, Insys announced that the FDA had accepted its NDA for the naloxone nasal spray for the treatment of opioid overdose.
Hikma President of Generics Brian Hoffmann said, “Hikma is the largest supplier of generic nasal sprays in the US and we have been looking for ways to build upon our strong manufacturing platform and expand our product portfolio. This acquisition adds unit-dose nasal spray manufacturing equipment, as well as two complex products to our pipeline. This new technology expands our existing nasal spray capabilities, creating a comprehensive platform, which we can leverage for both internal and partnership programs.”
Read the Hikma press release.
